Teicoplanin (PDF Version)
Glycopeptide
Staphylococcus aureus (teicoplanin susceptible), Coagulase negative Staphylococci, Streptococcus pneumoniae, Streptococcus spp., Enterococcus spp. (Teicoplanin susceptible), C. jeikeium, Clostridium spp., L. monocytogenes, Actinomyces
Teicoplanin inhibits polymerization of cell wall components in susceptible bacteria
Pharmacodynamics:
No data
Cmax: 53.5mg/L (after 3mg/kg dose); Half-life: 170 hours; Volume of distribution: 0.9-1.6L/kg; Protein binding: 90%
Skin: Hypersensitivity
Hepatic: Abnormal LFTs
Otic: Ototoxicity
Other: Drug fever
Dosing in adults:
Serious infections: 400mg-800mgIV q12h x 1-3 days, then maintenance dose daily
Dosing in pediatrics:
3-6mg/kg/day
Disease state based dosing:
Renal failure: CrCl > 60mL/min: Standard dosing
CrCl 40-60mL/min: half normal dose q24h
CrCl < 40mL/min: one-third maintenance dose given
Hepatic failure: No dosing changes recommended at this time.
Contraindications/Warnings/Precautions:
Warning: Cross allergenicity may occur between patient with true allergy to vancomycin and patients receiving teicoplanin
Drug Interactions:
Ciprofloxacin: Single case report of concomitant administration leading to seizure
Pregnancy:
Unknown
Monitoring Requirements:
Therapeutic: Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count
Toxic: Rare reports of ototoxicity. Audiograms recommended for long term therapy.
Brand names/Manufacturer: Targocid/Aventis Pharmaceuticals